Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15821223 | 0.81 | SLC5A2 (0.55) | SLC5A2 | |
| SCHEMBL18020636 | 0.81 | SLC5A2 (0.55) | SLC5A2 | |
| SCHEMBL12509841 | 0.79 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL12426127 | 0.79 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL17480486 | 0.79 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL14453052 | 0.79 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL18849224 | 0.76 | SLC5A2 (0.39) | SLC5A2 | |
| SCHEMBL21107749 | 0.76 | SLC5A2 (0.39) | SLC5A2 | |
| SCHEMBL19493416 | 0.76 | SLC5A2 (0.39) | SLC5A2 | |
| SCHEMBL12426051 | 0.76 | SLC5A2 (0.68) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170128414-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-11 | — | — | US | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20160089360-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-31 | — | — | US | disclosed |
| US-9174971-B2 | Process for the preparation of compounds useful as inhibitors of SGLT2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-03 | — | — | US | disclosed |
| US-9056850-B2 | Process for the preparation of compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-06-16 | — | — | US | disclosed |
| US-9024009-B2 | Process for the preparation of compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-05 | — | — | US | disclosed |
| US-20150011485-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-08 | — | — | US | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785403-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110087017-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-14 | — | — | US | disclosed |
| US-20110009347-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-01-13 | — | — | US | disclosed |
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | US | disclosed |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | Tanabe Pharma Corporation (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | SLC5A2 5/4885SLC5A1 13/4885 |
| US-20150011485-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20100099883-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | SLC5A2 5/4885SLC5A1 13/4885 |
| US-20160089360-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | SLC5A2 5/4885SLC5A1 13/4885 |
| US-20110087017-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT2 | SLC5A2, SLC5A1, SI | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | SLC5A2 5/4885SLC5A1 13/4885 |
| US-20170128414-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20110009347-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | SLC5A2 5/4885SLC5A1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.